Two Different Point-of-Care Test Devices for Malaria Show Why Emerging Technologies Can Be Disruptive to Clinical Pathology Laboratories

Separate research projects at University of Washington and in the United Kingdom are producing handheld diagnostic devices to accurately detect Malaria Two new handheld, point-of-care test (POC) devices for malaria  could save millions of lives in third-world countries. At the same time, these POC devices may lead to inexpensive alternatives for diagnosing common diseases in developed nations as well. Clinical laboratory test developers see a big opportunity in developing assays to detect...

Thermo Fisher to Buy Life Technologies for $13.6 Billion in Bid to Beef Up Its Share of Next-Generation Genetic Testing Market

Multi-billion-dollar mega-deal positions Thermo Fisher to offer a broader spectrum of gene sequencing systems to clinical laboratories and pathology groups Earlier this week, Thermo Fisher Scientific, Inc., (NYSE: TMO) of Waltham, Massachusetts, announced a deal that will shake up the market for next-generation gene sequencing and genetic testing. It will acquire Life Technologies Corporation (NASDAQ: LIFE) of Carlsbad, California. More IVD Industry Consolidation That Affects Clinical...

Legal Fight over Gene Patents in AMP vs. Myriad Case to Be Subject of Oral Hearings at the Supreme Court, Just Months after Its Ruling in Prometheus Case

Both pathology profession and biotech industry have much at stake in how Supreme Court rules in this important case involving the patentability of genes Legal challenges to gene patents are a high interest topic among pathologists and clinical laboratory scientists who perform genetic testing. Two high profile cases involving gene patents were accepted by the Supreme Court. A ruling was made in one case and the second case is continuing. The Supreme Court issued a ruling in one case, titled...

Federal Appeals Court Hears Arguments in the Myriad Genetics’ Gene Patent Case

At issue is ability of biotech companies to hold patents on genes that might be used in clinical laboratory testing Patents involving human genes have always been controversial among pathologists and clinical laboratory managers. This is one reason why many in the medical laboratory testing industry are following the progress of the well-publicized lawsuit that challenged certain patents involving human genes that are held by Myriad Genetics, Inc. (Myriad), of Salt Lake City, Utah. In the...

Pathology Labs Might Benefit from $1 Million Challenge to Sequence the Genome of a Single Cancer Cell

Goal is to produce accurate sequence of one human cancer cell; could lead to new cancer tests Pathologists and clinical laboratory managers will find the latest “prize” for a genetic breakthrough to have direct relevance to molecular diagnostics. One million dollars will go to the first person who sequences an entire cancer cell genome, including all of the RNA, using a specific whole human genome sequencer made by Carlsbad, California-based Life Technologies (NASDAQ: LIFE). This is the fourth...
;